|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Technological Evolution and Radical Innovation 显示文摘 | SOOD A TELLIS G J | 2005 | Journal of Marketing2005，69，1： | 1 |
| 2 | Research on Innovation:a Review and Agenda for Marketing Science显示文摘 | Hauser J Tellis G Griffin A | 2006 | Marketing Science2006，25，： | 1 |
| 3 | Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects显示文摘 | Tarcin OYD Ozben B Telli A | | 0，，10： | 1 |
| 4 | The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia显示文摘 | Aris P Agouridis Vasilis Tsimihodimos Theodosios D Filippatos Andromachi A Dimitriou Costantinos C Tellis Moses S Elisaf Dimitri P Mikhailidis Alexandros D Tselepis | 2011 | Expert Opinion on Pharmacotherapy2011，，17： | 1 |
| 5 | 早期乳腺癌最佳辅助化疗方案与人类表皮生长因子受体2阳性乳腺癌辅助靶向治疗选择:依据 ASCO 对 CCO临床实践指南的改编显示文摘目的研究加拿大安大略癌症治疗中心(CCO)关于早期乳腺癌最佳辅助化疗方案,包括人类表皮生长因子受体2(HER2)阳性乳腺癌辅助靶向治疗方案,并对其进行改编。方法按照美国临床肿瘤协会(ASCO)对其他组织临床实践指南改编的策略和程序,对CCO临床实践指南的严谨性与内容适用性进行回顾。结果基于对CCO临床实践指南内容的回顾,ASCO小组认为,CCO临床实践指南在整体上清晰全面,以最确切的科学证据为基础,为患者提供可接受的治疗选项。推荐关于辅助化疗方案的决定,应考虑到基线复发风险、毒性、利益可能性和宿主因素(如合并症)。对于高风险HER2阴性的身体状况良好的人群,蒽环类和紫杉烷治疗方案是标准治疗方案。4个周期的多西他赛和环磷酰胺治疗方案是可接受的非蒽环类治疗方案。对于高风险HER2阳性患者,推荐蒽环类与紫杉烷序贯疗法联合曲妥单抗或多西他赛、卡铂、曲妥单抗进行6个周期的治疗。对于低风险、非淋巴结转移、HER2阳性人群,推荐每周一次的紫杉醇和曲妥单抗连续进行12个周期的替代治疗。曲妥单抗应持续使用1年。不应采用铂复合盐对三阴性人群进行常规的辅助管理,除非出现有效的生存数据加以支持。 | Neelima Denduluri Mark R Somerfield Andrea Eisen Jamie N Holloway Arti Hurria Tari A King Gary H Lyman Ann H Partridge Melinda L Telli Maureen E Trudeau Antonio C Wolff 本刊编辑部 | 2016 | 中国全科医学2016，19，18： | 1 |
| 6 | Engagement of tumor necrosis factor(TNF)receptor 1 leads to ATF-2 and P38 MAPK-dependent TNF-α gene expression显示文摘 | Brinkman B M J B Tellie Z A R Schievella | 1999 | J Biol Chom1999，274，30： | 1 |
| 7 | Relative humidity sen-sors based on an environment-sensitive fluorophore in hydrogelfilms显示文摘 | Tellis J C Strulson C A Myers M M | 2011 | Anal Chem2011，83，： | 1 |
| 8 | Do Innovations Really Pay Off? Total Stock Market Returns to Innovation 显示文摘 | Sood A Tellis GJ | 2009 | Marketing Science2009，28，3： | 1 |
| 9 | Do innovations really pay off? total stock market returns to innovation 显示文摘 | SOOD A G J TELLIS | 2009 | Marketing Science2009，28，3： | 1 |
| 10 | Evaluation of the cytotoxicity of calcium phosphate root canal sealers by MTT assay 显示文摘 | Telli C Serper A Dogan AL | 1999 | J Endod1999，25，12： | 1 |
| 11 | Evaluation of the cytotoxicity of calcium phosphate root canal sealers by MTT assay显示文摘 | Telli C Serper A Dogan A L | 1999 | Journal of Endodontics1999，25，12： | 1 |
| 12 | Evaluation of the cytotoxicity of calcium phosphate root canal sealers by MTT assay 显示文摘 | Telli C Serper A Dogan AL | 1999 | J Endod1999，25，12： | 1 |
| 13 | Technological evolution and radical innovation 显示文摘 | Sood A Tellis G J | 2005 | Journal of Marketing2005，69，3： | 1 |
| 14 | Research on innova- tion: A review and agenda for marketing science 显示文摘 | Hauser J Tellis G J Griffin A | 2006 | Marketing science2006，25，6： | 1 |
| 15 | Research on innovation:A review and agenda for marketing science显示文摘 | Hauser J Tellis G J Griffin A | 2006 | Marketing science2006，25，： | 1 |
| 16 | Technological evolution and radical innovation显示文摘 | Sood A Tellis G J | 2005 | Journal of Marketing2005，，： | 1 |
| 17 | Preparation of deoxyni- valenol (vomitoxin) from field-inoculated corn 显示文摘 | Scott P M Lawrence G A Telli A | 1984 | J Assoc Off A- nal Chem1984，67，1： | 1 |
| 18 | Do Innovations Really Pay Off? Total Stock Market Returns to Innovation 显示文摘 | Sood A and G J Tellis | 2009 | Marketing Science2009，28，3： | 1 |
| 19 | Visceral leish-maniasismimicking autoimmune hepatitis,primary biliary cirrhosis,and systemic lupus erythematosus overlap显示文摘 | Tunccan OG Tufan A Telli G | 2012 | Korean J Para-sitol2012，50，10： | 1 |
| 20 | Phyllodes tumors ofthe breast:natural history,diagnosis,and treatment 显示文摘 | Telli M L Horst K C Guardino A E | 2007 | J NatlCompr Cane Netw2007，5，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员